Takeda Pharmaceutical Company Limited or Viatris Inc.: Who Leads in Yearly Revenue?

Takeda vs. Viatris: A Revenue Showdown

In the competitive landscape of the pharmaceutical industry, Takeda Pharmaceutical Company Limited and Viatris Inc. have emerged as key players. Over the past decade, Takeda has consistently outperformed Viatris in terms of annual revenue. From 2014 to 2023, Takeda's revenue surged by approximately 140%, peaking at over 4.26 trillion yen in 2023. In contrast, Viatris, despite its efforts, saw a more modest growth, with revenues increasing by about 100% to reach 15.4 billion yen in 2023.

A Decade of Growth

Takeda's strategic acquisitions and expansion into emerging markets have fueled its impressive growth trajectory. Meanwhile, Viatris, formed from the merger of Mylan and Upjohn in 2020, is still finding its footing in the global market. The data highlights Takeda's dominance, but Viatris's potential for future growth should not be underestimated.